Gain Therapeutics, Inc. Common Stock
GANXGain Therapeutics, Inc. (GANX) is a biotechnology company focused on developing innovative treatments for rare and underserved diseases. Utilizing its proprietary allosteric modulation platform, the company aims to discover and develop therapeutics that target enzymes and other proteins involved in disease pathways. Gain Therapeutics emphasizes precision medicine approaches to address unmet medical needs.
Company News
Gain Therapeutics will participate in the 2025 Maxim Growth Summit, with CEO Gene Mack joining a panel discussion on neurodegenerative diseases and presenting their lead drug candidate GT-02287 for Parkinson's disease treatment.
Gain Therapeutics presented positive Phase 1 data for its lead drug candidate GT-02287, which showed an increase in GCase activity in healthy volunteers, supporting its potential as a disease-modifying treatment for Parkinson's disease.
Gain Therapeutics, a clinical-stage biotechnology company, will host a webinar to discuss positive results from a Phase 1 study of its lead drug candidate GT-02287 for Parkinson's disease and the design of an upcoming Phase 1b trial.
Gain Therapeutics announced that it will present preclinical data on its lead drug candidate GT-02287 for the treatment of Parkinson's disease, including two late-breaking posters, at the Neuroscience 2024 conference.
Several healthcare stocks saw significant price movements in Thursday's pre-market session, with notable gainers including Autonomix Medical, Inspire Veterinary, and Salarius Pharmaceuticals, while Gain Therapeutics, Senti Biosciences, and Aspira Womens Health declined.
